Enanta is looking for a partner on its Covid pill after a PhII study disappoints
A biotech company with ambitions to compete with Pfizer’s blockbuster Covid-19 pill announced mixed results from a study of its experimental antiviral therapy and won’t carry forward with development of the drug on its own.
Enanta Pharmaceuticals said Monday that its pill, EDP-235, met its primary endpoints of safety and tolerability in its Phase II trial, dubbed SPRINT, but yielded mixed results on its effectiveness. It failed to clear the virus faster than a placebo and failed to speed up recovery of 14 symptoms of Covid, although the company emphasized that the treatment appeared to improve a subset of symptoms.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.